nach oben

Clinical Pharmacokinetics

Erschienen in:

01.11.2003 | Review Article

Macromolecular Therapeutics

Advantages and Prospects with Special Emphasis on Solid Tumour Targeting

verfasst von: Khaled Greish, Jun Fang, Takao Inutsuka, Akinori Nagamitsu, Professor Hiroshi Maeda

Erschienen in: Clinical Pharmacokinetics | Ausgabe 13/2003

Einloggen, um Zugang zu erhalten

Abstract

Macromolecular drugs (also referred to as polymeric drugs) are a diverse group of drugs including polymer-conjugated drugs, polymeric micelles, liposomal drugs and solid phase depot formulations of various agents. In this review we will consider only water-soluble macromolecular drugs. In common, such drugs have high molecular weights, more than 40 kDa, which enables them to overcome renal excretion. Consequently, this group of drugs can attain prolonged plasma or local half-lives.

The prolonged circulating time of these macromolecules enables them to utilise the vascular abnormalities of solid tumour tissues, a phenomenon called the enhanced permeability and retention (EPR) effect. The EPR effect facilitates extravasation of polymeric drugs more selectively at tumour tissues, and this selective targeting to solid tumour tissues may lead to superior therapeutic benefits with fewer systemic adverse effects. This contrasts with conventional low-molecular-weight drugs, where intratumour concentration diminishes rapidly in parallel with plasma concentration. The EPR effect is also operative in inflammatory tissues, which justifies the development and use of this class of drugs in infectious and inflammatory conditions.

At the present time, several polymeric drugs have been approved by regulatory agencies. These include zinostatin stimalamer (copolymer styrene maleic acid-conjugated neocarzinostatin, or SMANCS) and polyethyleneglycol-conjugated interferon-α-2a. This article discusses these and other polymeric drugs in the setting of targeting to solid tumours.

Use of tradenames is for product identification only and does not imply endorsement

World Health Organization. Press release WHO/52, 28 June 2002. Available online from: http://www.who.int/inf/en/pr-2002-52.html [Accessed 2003 Aug 23]

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and antitumor agent SMA-neocarzinostatin. Cancer Res 1986; 46: 6387–92PubMed

Noguchi Y, Wu J, Duncan R, et al. Early phase of tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998; 89: 307–14PubMedCrossRef

Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 1984; 44: 2114–21

Folkman J. Tumor angiogenesis in cancer, therapeutic implications. N Engl J Med 1971; 285: 1182–6PubMedCrossRef

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31PubMedCrossRef

Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 1998; 58: 159–65PubMed

Maeda H, Akaike T, Wu J, et al. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 1996; 33: 222–30PubMedCrossRef

Matsumura Y, Kimura M, Yamamoto T, et al. Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 1988; 79: 1327–34PubMedCrossRef

10.

Maeda H, Matsumura Y, Kato H. Purification and identification of [hydroxypropyl 3] bradykinin in ascitic fluid from a patient with gastric cancer. Jpn J Cancer Res 1994; 85: 331–4PubMedCrossRef

11.

Doi K, Akaike T, Horie H, et al. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 1996; 77: 1598–04PubMedCrossRef

12.

Doi K, Akaike T, Fujii S, et al. Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumors and implications for tumor growth. Br J Cancer 1999; 80: 1945–54PubMedPubMedCentralCrossRef

13.

Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–5PubMedCrossRef

14.

Wu J, Akaike T, Hyashida K, et al. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 2001; 92: 439–51PubMedCrossRef

15.

Arshady R, editor. Polymeric biomaterials, the PBM Series, Vol 1: introduction to polymeric biomaterials. London: Citus Books, 2003: 233–61

16.

Maeda H, Kabanov A, Kataoka K, et al., editors. Polymer drugs in the clinical stage: advantages and prospects. New York: Kluwer Academic, 2003

17.

Schechter B, Neumann A, Wilchek M, et al. Soluble polymers as carriers of cisplatinum. J Control Release 1989; 10: 75–87CrossRef

18.

Li C, Yu DF, Newman R, et al. Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998; 58: 2404–9PubMed

19.

Singer JW, De Vries P, Bhatt R, et al. Conjugation of camptothecins to poly-(L-glutamic acid). Ann N Y Acad Sci 2000; 922: 136–50PubMedCrossRef

20.

Al-Shamkhani A, Duncan R. Alginates as a macromolecular drug delivery system for the antitumor agent daunomycin: synthesis, controlled release properties and antitumor activity of alginate-cis-aconityl-daunomycin conjugates. Int J Pharm 1995; 122: 107–19CrossRef

21.

Ohya Y, Inosaka K, Ouchi T. Synthesis and antitumor activity of 6-O-carboxymethyl chitin fixing 5-fluorouracil through pentamethylene, monomethylene spacer groups via amide, ester bonds. Chem Pharm Bull (Tokyo) 1992; 40: 559–61CrossRef

22.

Yashima E, Uchida S, Akashi M, et al. Polymer drugs and polymeric drugs. Part VII. Antitumour conjugated polymeric drugs consisting of 5-fluorouracil and polyanionic polymers. J Bioact Compat Polym 1990; 5: 53–64CrossRef

23.

Danhauser-Riedl S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993; 11: 187–95PubMedCrossRef

24.

Munechika K, Sogame Y, Kishi N, et al. Tissue distribution of macromolecular conjugate adriamycin linked to oxidized dextran, in rat and mouse bearing tumor-cells. Biol Pharm Bull 1994; 17: 1193–8PubMedCrossRef

25.

Bernstein A, Hurwitz E, Arnon R. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J Natl Cancer Inst 1978; 60: 379–84PubMedCrossRef

26.

Takakura Y, Atsumi R, Hashida M, et al. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge: II. disposition and pharmacokinetics following intravenous and intramuscular administration. Int J Pharm 1987; 37: 145–54CrossRef

27.

Takakura Y, Kitajima M, Matsumoto S, et al. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge: I. physicochemical characteristics and in vivo and in vitro antitumour activities. Int J Pharm 1987; 37: 135–43CrossRef

28.

Okuno S, Harada M, Yano T, et al. Complete regression of xenografted human carcinomas by camptothecin analoguecarboxymethyl dextran conjugate (T-0128). Cancer Res 2000; 60: 2988–95PubMed

29.

Schechter B, Pauzner R, Arnon R, et al. Cisplatinum (II) complexes of carboxymethyl dextran as potential antitumor agents: I. Preparation and characterization. Cancer Biochem Biophys 1986; 8: 277–87PubMed

30.

Ichinose K, Tomiyama N, Nakashima M, et al. Antitumor activity of dextran derivatives immobilizing platinum complex (II). Anticancer Drags 2000; 11: 33–8CrossRef

31.

Nogusa H, Yano T, Okuno S, et al. Synthesis of carboxymethylpullulan-peptide-doxorabicin conjugates and their properties. Chem Pharm Bull 1995; 43: 1931–6PubMedCrossRef

32.

Nogusa H, Hamana H, Uchida N, et al. Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpullulan-peptide-doxorabicin conjugates. Jpn J Cancer Res 2000; 91: 1333–8PubMedCrossRef

33.

Hirano T, Ringsdorf H, Zaharko D. Antitumor activity of monomeric and polymeric cyclophosphamide derivative compound with in vitro hydrolysis. Cancer Res 1980; 40: 2263–7PubMed

34.

Pratesi G, Tortoreto M, Zunino F. Increased effect of doxorubicin linked to pyran copolymer in the intracavity treatment of human ovarian carcinoma in nude mice. Reg Cancer Treat 1990; 3: 40–3

35.

Duncan R, Hume IC, Yardley HJ, et al. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl) methacrylamide copolymers. J Control Release 1991; 16: 121–36CrossRef

36.

Putnam DA, Kopecek J. Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl) methacrylamide-based copolymers via lysosomal enzymes. Bioconjug Chem 1995; 6: 483–92PubMedCrossRef

37.

Vasey P, Kaye S, Morrison R, et al. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorabicin): first member of a new class of chemotherapeutic agents-drag-polymer conjugates. Clin Cancer Res 1999; 5: 83–94PubMed

38.

Kopecek J, Kopeckova P, Minko T, et al. HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000; 50: 61–81PubMedCrossRef

39.

Caiolfa VR, Zamai M, Fiorino A, et al. Polymer-bound camptothecin: initial biodistribution and antitumor activity studies. J Control Rel 2000; 65: 105–19CrossRef

40.

Greenwald RB, Gilbert CW, Pendri A, et al. Drag delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs -design and in vivo effectiveness. J Med Chem 1996; 39: 424–31PubMedCrossRef

41.

Li C, Yu D, Inoue T, et al. Synthesis and evaluation of watersoluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrag. Anticancer Drags 1996; 7: 642–8CrossRef

42.

Pendri A, Conover CD, Greenwald RB. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly (ethylene glycol): a water-soluble prodrag. Anticancer Drag Des 1998; 13: 387–95

43.

Zhang X, Burt HM, Mangold G, et al. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drags 1997; 8: 696–01CrossRef

44.

Ramaswamy M, Zhang X, Burt HM, et al. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 1997; 86: 460–4PubMedCrossRef

45.

Zhang X, Burt HM, Von Hoff D, et al. An investigation of the antitumor activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol 1997; 40: 81–6PubMedCrossRef

46.

Mizumura Y, Matsumura Y, Hamaguchi T, et al. Cisplatinincorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 2001; 92: 328–36PubMedCrossRef

47.

Yokoyama M, Miyauchi M, Yamada N, et al. Characterization and antitumor activity of the micelle-forming polymeric anticancer drag doxorubicin-conjugated poly (ethylene glycol)-poly (aspartic acid) block copolymer. Cancer Res 1990; 50: 1693–00PubMed

48.

Yokoyama M, Okano T, Sakurai Y, et al. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 1991; 51: 3229–36PubMed

49.

Yokoyama M, Okano T, Sakurai Y, et al. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drag Target 1999; 7: 171–86CrossRef

50.

Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002 Sep 13; 54: 715–58PubMedCrossRef

51.

Fischer D, Li Y, Ahlemeyer B, et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003; 24: 1121–31PubMedCrossRef

52.

Kopecek J, Kopeckova P, Minko T, et al. Water-soluble polymers in tumor targeted delivery. J Control Release 2001 Jul 6; 74: 147–58PubMedCrossRef

53.

Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424–36PubMedCrossRef

54.

Brocchini S, Duncan R. Pendent drugs, release from polymers. In: Mathiowitz E, editor. Encyclopedia of controlled drug delivery. New York: John Wiley & Sons Inc, 1999: 786–816

55.

Sawa T, Sahoo SK, Maeda H. Water-soluble polymer in medicine. In: Arshady R, editor. Polymeric biomaterials, The PBM Series, Vol 1: introduction to polymeric biomaterials. London: Citus Books, 2003: 233–61

56.

Maeda H, Matsumura Y, Oda T, et al. Cancer selective macromolecular therapeutics: tailoring of an antitumor protein drug. In: Feeny RE, Whitaker JR, editors. Protein tailoring for food and medical uses. New York: Marcel Dekker Inc, 1986: 353–82

57.

Maeda H, Takeshita J, Kimura M. Improvement of pharmacological properties of protein drags by tailoring with synthetic polymers. J Bioact Compat Polym 1988; 3: 27–43CrossRef

58.

Bartholeyns J, Moore S. Pancreatic ribonuclease: enzymatic and physiological properties of cross-linked dimer. Science 1974; 186: 444–5PubMedCrossRef

59.

Takakura T, Kaneko Y, Hashida M, et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran: I. synthesis and characterization. J Pharm Sci 1989; 78: 117–21PubMedCrossRef

60.

Takakura T, Fujita T, Hashida M, et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran II. Biopharmaceutical and pharmacological properties. J Pharm Sci 1989; 78: 219–22PubMedCrossRef

61.

Ogino T, Inoue M, Ando Y, et al. Chemical modification of Superoxide dismutase: extension of plasma half-life of the enzyme through its reversible binding to the circulating albumin. Int J Pept Protein Res 1988; 32: 153–9PubMedCrossRef

62.

Kimura M, Matsumora Y, Miyauchi Y, et al. A new tactic for the treatment of jaundice: an injectable polymer-conjugated bilirubin oxidase. Pro Soc Exp Biol Med 1988; 188: 364–9CrossRef

63.

Buys CHCM, Dejong ASH, Bouma JDW, et al. Rapid uptake by liver sinusoidal cells of serum albumin modified with retention of its compact conformation. Biochim Biophys Acta 1975; 392: 95–100PubMedCrossRef

64.

Kamisaki Y, Wada H, Yagura H, et al. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxy polyethylene glycol. J Pharmacol Exp Ther 1981; 216: 410–4PubMed

65.

Ney K, Gidwitz S, Pizzo S. Binding and endocytosis of α₂-nacroglobulin-plasmin complex. Biochemistry 1985; 24: 4586–92PubMedCrossRef

66.

Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390–9PubMedCrossRef

67.

Glue P, Fang J, Sabo WS, et al. Pegylated interferon-α2b: pharmacokinetics, pharmaco-dynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556–67PubMedCrossRef

68.

Heathcote EJ, Shiftman ML, Coooksley WG, et al. PEG-interferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–80PubMedCrossRef

69.

Duncan R, Rejmanova P, Kopecek J, et al. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl) methacrylamide copolymers: a potential drug delivery system. Biochim Biophys Acta 1981; 678: 143–50PubMedCrossRef

70.

Maeda H, Aikawa S, Yamashita A. Subcellular fate of protein antibiotic neocarzinostatin in culture of lymphoid cell line from Burkett’s lymphoma. Cancer Res 1975; 35: 554–9PubMed

71.

Oda T, Maeda H. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its action by conjugation with lipophilic styrene-maleic acid copolymer. Cancer Res 1987; 47: 3206–11PubMed

72.

Pellegrin P, Fernandez A, Lamb NJ, et al. Macromolecular uptake is a spontaneous event during mitosis in cultured fibroblasts: implications for vector-dependent plasmid transfection. Mol Biol Cell 2002; 13: 570–8PubMedPubMedCentralCrossRef

73.

Miyamoto Y, Oda T, Maeda H. Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res 1990; 150: 1571–5

74.

St’astny M, Strohalm J, Plocova D, et al. Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur J Cancer 1999; 35: 459–66PubMedCrossRef

75.

Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990 Jan 3; 82: 4–6PubMedCrossRef

76.

Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74: 47–61PubMedCrossRef

77.

Maeda H. Enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189–07PubMedCrossRef

78.

Maeda H, Fang J, Inuzuka T, et al. Vascular permeability enhancement in solid tumors: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319–28PubMedCrossRef

79.

Jain R. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58–65PubMedCrossRef

80.

Seymour LW, Miyamoto Y, Maeda H, et al. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995; 31A: 766–70PubMedCrossRef

81.

Duncan R. Polymer conjugates for tumor targeting and intercytoplasmic delivery: the EPR effect as a common gateaway?. Pharm Sci Technol Today 1999; 2(11): 441–9PubMedCrossRef

82.

Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752–6PubMed

83.

Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363–80PubMedPubMedCentralCrossRef

84.

Ohkouchi K, Imoto H, Takakura Y, et al. Disposition of anticancer drugs after bolus arterial administration in a tissueisolated tumor perfusion system. Cancer Res 1990; 50: 4396–401

85.

Konno T, Maeda H, Iwai K, et al. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984; 54: 2367–74PubMedCrossRef

86.

Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 1991; 6: 181–02CrossRef

87.

Iwai K, Maeda H, Konno T, et al. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res 1987; 7: 321–7PubMed

88.

Marecos E, Weissleder R, Bogdanov A. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconjug Chem 1998; 9: 184–91PubMedCrossRef

89.

Skinner S, Tutton P, O’Brien PE. Microvascular architecture of experimental colon tumors in the rat. Cancer Res 1990; 50: 2411–7PubMed

90.

Suzuki M, Takahashi T, Sato T. Medial regression and its functional significance in tumor supplying host arteries. Cancer 1987; 59: 444–50PubMedCrossRef

91.

Li CJ, Miyamoto Y, Kojima Y, et al. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 1993; 67: 975–80PubMedPubMedCentralCrossRef

92.

Maeda H, Wu J, Okamoto T, et al. Kallikrein-kinin in infection and cancer. Immunopharmacology 1999; 43: 115–28PubMedCrossRef

93.

Suzuki M, Hori K, Abe Z, et al. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981; 67: 663–9PubMed

94.

Hori K, Saito S, Takahashi H, et al. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res 2000; 91: 261–9PubMedCrossRef

95.

Hori K, Suzuki M, Tanda S, et al. Fluctuation in tumor blood flow under normotension and the effect of angiotensin-II induced hypertension. Jpn J Cancer Res 1991; 82: 1309–16PubMedCrossRef

96.

Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002; 98: 29–35PubMedCrossRef

97.

Kamata R, Yamamoto T, Matsumoto K, et al. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pig. Infect Immun 1985; 48: 747–53PubMedPubMedCentral

98.

Tanaka S, Akaike T, Wu J, et al. Tumor selective vascular blood flow modulation accompanying extravasation induced by stable prostaglandin I₂analogue, beraprost sodium. J Drug Target 2003; 11: 45–52PubMedCrossRef

99.

Yamaguchi T, Takahashi T, Kitamura K, et al. Application of tumor marker for immunotargeting therapy of cancer. Nippon Rinsho 1996; 54: 1674–9PubMed

100.

Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750–63PubMedCrossRef

101.

Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology 2002; 63 Suppl. 1: 17–24PubMedCrossRef

102.

King KM, Younes A. Rituximab: review and clinical applications focusing on non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther 2001; 1: 177–86PubMedCrossRef

103.

Maeda H. Neocarzinostatin in cancer chemotherapy (review). Anticancer Res 1981; 1: 175–86PubMed

104.

Edo K, Koide Y. Neocarzinostatin chromophore: structure and mechanism of DNA cleavage. In: Maeda H, Edo K, Ishida N, editors. Neocarzinostatin: the past, present, and future of an anticancer drug. Tokyo: Springer-Verlag, 1997: 23–45CrossRef

105.

Maeda H, Ueda M, Morinaga T, et al. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J Med Chem 1985; 28: 455–61PubMedCrossRef

106.

Oda T, Morinaga T, Maeda H. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc Soc Exp Biol Med 1986; 181: 9–17PubMedCrossRef

107.

Oda T, Sato F, Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J Natl Cancer Inst 1987; 79: 1205–11PubMed

108.

Oka K, Miyamoto Y, Matsumura Y, et al. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, SMANCS, in an oily formulation. Pharm Res 1990; 7: 852–5PubMedCrossRef

109.

Kobayashi A, Oda T, Maeda H. Protein binding of macromolecular anticancer agent SMANCS: characterization of poly (styrene-co-maleic acid) derivatives as an albumin binding ligand. J Bioact Compat Polym 1988; 3: 319–33CrossRef

110.

Maeda H, Matsumoto T, Konno T, et al. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J Protein Chem 1984; 3: 181–93CrossRef

111.

Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053–65PubMedCrossRef

112.

Maki S, Konno T, Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985; 56: 751–7PubMedCrossRef

113.

Konno T, Kai Y, Yamashita R, et al. Targeted chemotherapy for unresectable primary and metastatic liver cancer. Acta Oncol 1994; 33: 133–7PubMedCrossRef

114.

Seymour LW, Olliff SP, Poole CJ, et al. A novel dosage approach for evaluation of SMANCS in the treatment of primary hepatocellular carcinoma. Int J Oncol 1998; 12: 1217–23PubMed

115.

Reddy K, Wright T, Pockros P, et al. Efficacy and safety of pegylated (40-kDa) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433–8PubMedCrossRef

116.

Karasiewicz R, Nalin C, Rosen P. PEG-interferon conjugates, compound no. (Ro25-2854, Ro24-9485). US Patent 5,382,657. 1995 Jan 17

117.

Rajender R, Modi M, Pedder S. Use of peginterferon α-2a (40KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002; 54: 571–86CrossRef

118.

Fried M, Shiffman M, Reddy K, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82PubMedCrossRef

119.

Zeuzem S, Feinman SV, Rasenack J, et al. PEG-interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–772PubMedCrossRef

120.

Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest 2002; 20: 859–60CrossRef

121.

Matsumora Y. An interim analysis of phase I clinical trial of MCC-456, doxorubicin encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. In: Maeda H, Kabanov A, Kataoka K, et al. editors. Polymer drugs in the clinical stage: advantages and prospects. New York: Kluwer Academic, 2003: 179–94

122.

Hershfield MS, Buckley R, Greenberg M, et al. Treatment of adenosine deaminase deficiency with polyethylene glycolmodified adenosine deaminase. N Engl J Med 1987; 310: 586–9

123.

Abuchowski A, Kazo G, Verhowest J, et al. Cancer therapy with chemically modified enzymes: I. antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984; 7: 175–86PubMed

Titel: Macromolecular Therapeutics
Advantages and Prospects with Special Emphasis on Solid Tumour Targeting
verfasst von: Khaled Greish
Jun Fang
Takao Inutsuka
Akinori Nagamitsu
Professor Hiroshi Maeda
Publikationsdatum: 01.11.2003
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 13/2003
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200342130-00002

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2003

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation

Absorption Enhancers for Nasal Drug Delivery

Clinical Pharmacokinetics of Atorvastatin

Dietary Effects on Drug Metabolism and Transport